Candel Therapeutics (CADL) Net Income towards Common Stockholders: 2020-2024
Historic Net Income towards Common Stockholders for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to -$30.2 million.
- Candel Therapeutics' Net Income towards Common Stockholders rose 31.61% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 3.54%. This contributed to the annual value of -$30.2 million for FY2024, which is 10.44% up from last year.
- Per Candel Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$30.2 million for FY2024, which was up 10.44% from -$33.7 million recorded in FY2023.
- Over the past 5 years, Candel Therapeutics' Net Income towards Common Stockholders peaked at -$13.7 million during FY2020, and registered a low of -$35.2 million during FY2022.
- For the 3-year period, Candel Therapeutics' Net Income towards Common Stockholders averaged around -$33.0 million, with its median value being -$33.7 million (2023).
- As far as peak fluctuations go, Candel Therapeutics' Net Income towards Common Stockholders crashed by 88.18% in 2021, and later rose by 10.44% in 2024.
- Candel Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$13.7 million in 2020, then slumped by 88.18% to -$25.8 million in 2021, then plummeted by 36.59% to -$35.2 million in 2022, then grew by 4.25% to -$33.7 million in 2023, then increased by 10.44% to -$30.2 million in 2024.